Recombinant Human OCIL/CLEC2d Fc Chimera Protein, CF Summary
Accession # Q9UHP7.1
Complete Your Research
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 250 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
When Recombinant Human CD161 Fc Chimera Protein (7448-CD) is immobilized at 10 μg/mL (100 μL/well), the concentration of Recombinant Human OCIL/CLEC2d Fc Chimera (Catalog # 10506-OC) that produces 50% of the optimal binding response is approximately 1.5-9 μg/mL.
C-type lectin domain family 2 member D (CLEC2D), also known as lectin-like NK cell receptor,as lectin-like transcript 1 (LLT-1) and osteoclast inhibitory lectin (OCIL), is a member of the C-type lectin like (CTL) superfamily of natural killer cell receptors (1, 2). Human OCIL/CLEC2D is highly glycosylated and consists of a cytoplasmic domain, a type II transmembrane domain, a stalk region and a C-type lectin-like (CTL) in the extracellular domain (ECD). Within the ECD, mature human OCIL/CLEC2D shares 45% and 43% amino acid sequence identity with mouse and rat OCIL/CLEC2D, respectively. At least six different isoforms of OCIL/CLEC2D, resulting from alternatively spicing, have been reported (1, 2). OCIL/ CLEC2D plays a role in immunotherapy, inflammation and tissue injury and is expressed mainly on activated lymphocytes (NK cells, T cells, B cells) and antigen presenting cells (1-6).OCIL/CLEC2D forms a disulfide linked homodimer that acts as the only ligand for NKRP1A (CD161) and inhibits NK cell-mediated cytotoxicity and IFN-gamma secretion (1,6,7). OCIL/CLEC2D preferentially binds high molecular weight sulfated glycosaminoglycans and blocks osteoclast differentiation (1, 4).
- Marrufo, A. et al. (2018) Am. J. Cancer Res. 8:1050.
- Germain, C. et al. (2010) J. Biol. Chem. 285:36207.
- Mathew, S. et al. (2016) Oncotarget 7:68650.
- Lai, J. et al. (2020) Immunity 52:123.
- Varaden, D. et al. (2019) Eur. J. Obstet. Gynecol. Reprod. Biol. X. 3:100039.
- Sun, Y. et al. (2019) J. Cancer Metastasis Treat. 5:80.
- Skalova, T. et al. (2015) Acta. Crystallogr. D. Biol. Crystallogr. 71:578.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human OCIL/CLEC2d Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human OCIL/CLEC2d Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human OCIL/CLEC2d Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image